Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
Andrés Muñoz MartinLaura Ortega MoránAna GutiérrezEnrique GallardoDarío Rubio-RodríguezCarlos Rubio-TerrésBlanca MorónPilar García AlfonsoJosé Manuel SoriaPublished in: Journal of medical economics (2023)
In thromboprophylaxis of cancer patients, the use of apixaban and rivaroxaban generated similar cost compared to non-prophylaxis, without the difference found being statistically significant, with a clinically insignificant QALY gain.